Cat. No.: DAB-0012992
Product Information | |
---|---|
Clonality | Polyclonal |
Isotype | IgG |
Host Species | Goat |
Reactivity | Human |
Product Description | Synthetic peptide C-HQWLKDKNKGEIYD from the internal region of human PI3-kinase p110 subunit alpha (NP_006209.2). |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | PIK3CA |
UniProt No. | P42336 |
Gene ID | 5290 |
Gene Description | Phosphoinositide 3-kinase catalyzes the production of phosphatidylinositol-3, 4, 5-triphosphate by phosphorylating phosphatidylinositol, phosphatidylinositol-4-phosphate, and phosphatidylinositol-4, 5-bisphosphate. Growth factors and hormones trigger this phosphorylation event, which in turn coordinates cell growth, cell cycle entry, cell migration, and cell survival. PTEN reverses this process, and research studies have shown that the PI3K signaling pathway is constitutively activated in human cancers that have loss of function of PTEN. PI3Ks are composed of a catalytic subunit and a regulatory subunit. Various isoforms of the catalytic subunit have been isolated, and the regulatory subunits that associate with p110α, p110β, and p110δ are p85α and p85β. In contrast, p110γ associates with a p101 regulatory subunit that is unrelated to p85. Furthermore, p110γ is activated by βγ subunits of heterotrimeric G proteins. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | This product is shipped at ambient temperature. It is recommended to aliquot and store at -20 °C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8 °C for short term use (up to 4 weeks) and store the remaining aliquots at -20 °C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. |
Storage Buffer | TRIS buffered saline 0.02% Sodium Azide (NaN3) 0.5% Bovine Serum Albumin |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.